vs
Amphastar Pharmaceuticals, Inc.（AMPH）とPOWER SOLUTIONS INTERNATIONAL, INC.（PSIX）の財務データ比較。上の社名をクリックして会社を切り替えられます
POWER SOLUTIONS INTERNATIONAL, INC.の直近四半期売上が大きい（$191.2M vs $183.1M、Amphastar Pharmaceuticals, Inc.の約1.0倍）。Amphastar Pharmaceuticals, Inc.の純利益率が高く（13.3% vs 8.4%、差は4.9%）。POWER SOLUTIONS INTERNATIONAL, INC.の前年同期比売上増加率が高い（32.5% vs -1.8%）。Amphastar Pharmaceuticals, Inc.の直近四半期フリーキャッシュフローが多い（$24.6M vs $-7.6M）。過去8四半期でPOWER SOLUTIONS INTERNATIONAL, INC.の売上複合成長率が高い（41.7% vs 3.2%）
Amphastar Pharmaceuticalsは上場されている米国の特殊製薬企業です。2004年5月に設立され、主に吸入剤および鼻腔内投与製品の開発、生産、販売を行っており、特色ある医薬品分野で事業を展開しています。
アダニ・エナジー・ソリューションズ株式会社（旧称：アダニ送電株式会社）は電力の送配電事業を営む企業で、本社はアフマダーバードに所在します。2025年4月時点で累計26,696回路キロメートルの送電網を運用しており、インド最大級の民間部門送電会社の1つです。
AMPH vs PSIX — 直接比較
損益計算書 — Q4 FY2025 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $183.1M | $191.2M |
| 純利益 | $24.4M | $16.1M |
| 粗利率 | 46.8% | 21.9% |
| 営業利益率 | 19.4% | 12.7% |
| 純利益率 | 13.3% | 8.4% |
| 売上前年比 | -1.8% | 32.5% |
| 純利益前年比 | -35.7% | -31.0% |
| EPS（希薄化後） | $0.51 | $0.69 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $183.1M | $191.2M | ||
| Q3 25 | $191.8M | $203.8M | ||
| Q2 25 | $174.4M | $191.9M | ||
| Q1 25 | $170.5M | $135.4M | ||
| Q4 24 | $186.5M | $144.3M | ||
| Q3 24 | $191.2M | $125.8M | ||
| Q2 24 | $182.4M | $110.6M | ||
| Q1 24 | $171.8M | $95.2M |
| Q4 25 | $24.4M | $16.1M | ||
| Q3 25 | $17.4M | $27.6M | ||
| Q2 25 | $31.0M | $51.2M | ||
| Q1 25 | $25.3M | $19.1M | ||
| Q4 24 | $38.0M | $23.3M | ||
| Q3 24 | $40.4M | $17.3M | ||
| Q2 24 | $37.9M | $21.5M | ||
| Q1 24 | $43.2M | $7.1M |
| Q4 25 | 46.8% | 21.9% | ||
| Q3 25 | 51.4% | 23.9% | ||
| Q2 25 | 49.6% | 28.2% | ||
| Q1 25 | 50.0% | 29.7% | ||
| Q4 24 | 46.5% | 29.9% | ||
| Q3 24 | 53.3% | 28.9% | ||
| Q2 24 | 52.2% | 31.8% | ||
| Q1 24 | 52.4% | 27.0% |
| Q4 25 | 19.4% | 12.7% | ||
| Q3 25 | 13.2% | 13.9% | ||
| Q2 25 | 24.2% | 16.9% | ||
| Q1 25 | 21.9% | 18.2% | ||
| Q4 24 | 24.2% | 17.5% | ||
| Q3 24 | 29.8% | 16.3% | ||
| Q2 24 | 30.3% | 22.9% | ||
| Q1 24 | 27.9% | 11.2% |
| Q4 25 | 13.3% | 8.4% | ||
| Q3 25 | 9.0% | 13.5% | ||
| Q2 25 | 17.8% | 26.7% | ||
| Q1 25 | 14.8% | 14.1% | ||
| Q4 24 | 20.4% | 16.1% | ||
| Q3 24 | 21.1% | 13.8% | ||
| Q2 24 | 20.8% | 19.5% | ||
| Q1 24 | 25.1% | 7.5% |
| Q4 25 | $0.51 | $0.69 | ||
| Q3 25 | $0.37 | $1.20 | ||
| Q2 25 | $0.64 | $2.22 | ||
| Q1 25 | $0.51 | $0.83 | ||
| Q4 24 | $0.74 | $1.01 | ||
| Q3 24 | $0.78 | $0.75 | ||
| Q2 24 | $0.73 | $0.94 | ||
| Q1 24 | $0.81 | $0.31 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $282.8M | $41.3M |
| 総負債低いほど良い | $608.7M | $96.6M |
| 株主資本純資産 | $788.8M | $178.6M |
| 総資産 | $1.6B | $424.7M |
| 負債/資本比率低いほどレバレッジが低い | 0.77× | 0.54× |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $282.8M | $41.3M | ||
| Q3 25 | $276.2M | $49.0M | ||
| Q2 25 | $231.8M | $49.5M | ||
| Q1 25 | $236.9M | $50.0M | ||
| Q4 24 | $221.6M | $55.3M | ||
| Q3 24 | $250.5M | $40.5M | ||
| Q2 24 | $217.8M | $28.8M | ||
| Q1 24 | $289.6M | $33.1M |
| Q4 25 | $608.7M | $96.6M | ||
| Q3 25 | $608.6M | $96.7M | ||
| Q2 25 | $607.7M | $1.8M | ||
| Q1 25 | $603.9M | $1.0M | ||
| Q4 24 | $601.6M | $184.0K | ||
| Q3 24 | $596.4M | $238.0K | ||
| Q2 24 | $586.9M | $292.0K | ||
| Q1 24 | $594.0M | $345.0K |
| Q4 25 | $788.8M | $178.6M | ||
| Q3 25 | $776.7M | $162.5M | ||
| Q2 25 | $757.5M | $135.7M | ||
| Q1 25 | $751.3M | $84.3M | ||
| Q4 24 | $732.3M | $65.3M | ||
| Q3 24 | $727.7M | $42.1M | ||
| Q2 24 | $713.3M | $24.8M | ||
| Q1 24 | $672.4M | $3.2M |
| Q4 25 | $1.6B | $424.7M | ||
| Q3 25 | $1.7B | $458.9M | ||
| Q2 25 | $1.6B | $437.7M | ||
| Q1 25 | $1.6B | $372.7M | ||
| Q4 24 | $1.6B | $328.2M | ||
| Q3 24 | $1.5B | $339.1M | ||
| Q2 24 | $1.5B | $307.6M | ||
| Q1 24 | $1.6B | $286.8M |
| Q4 25 | 0.77× | 0.54× | ||
| Q3 25 | 0.78× | 0.60× | ||
| Q2 25 | 0.80× | 0.01× | ||
| Q1 25 | 0.80× | 0.01× | ||
| Q4 24 | 0.82× | 0.00× | ||
| Q3 24 | 0.82× | 0.01× | ||
| Q2 24 | 0.82× | 0.01× | ||
| Q1 24 | 0.88× | 0.11× |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $32.9M | $-4.6M |
| フリーキャッシュフロー営業CF - 設備投資 | $24.6M | $-7.6M |
| FCFマージンFCF / 売上 | 13.4% | -4.0% |
| 設備投資強度設備投資 / 売上 | 4.5% | 1.6% |
| キャッシュ転換率営業CF / 純利益 | 1.35× | -0.29× |
| 直近12ヶ月FCF直近4四半期 | $121.2M | $14.1M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $32.9M | $-4.6M | ||
| Q3 25 | $52.6M | $3.3M | ||
| Q2 25 | $35.6M | $16.7M | ||
| Q1 25 | $35.1M | $8.8M | ||
| Q4 24 | $29.0M | $32.7M | ||
| Q3 24 | $60.0M | $12.6M | ||
| Q2 24 | $69.1M | $1.5M | ||
| Q1 24 | $55.3M | $15.6M |
| Q4 25 | $24.6M | $-7.6M | ||
| Q3 25 | $47.2M | $1.7M | ||
| Q2 25 | $25.0M | $14.6M | ||
| Q1 25 | $24.4M | $5.4M | ||
| Q4 24 | $16.6M | $30.0M | ||
| Q3 24 | $46.2M | $12.1M | ||
| Q2 24 | $63.1M | $822.0K | ||
| Q1 24 | $46.5M | $14.8M |
| Q4 25 | 13.4% | -4.0% | ||
| Q3 25 | 24.6% | 0.8% | ||
| Q2 25 | 14.3% | 7.6% | ||
| Q1 25 | 14.3% | 4.0% | ||
| Q4 24 | 8.9% | 20.8% | ||
| Q3 24 | 24.1% | 9.7% | ||
| Q2 24 | 34.6% | 0.7% | ||
| Q1 24 | 27.1% | 15.6% |
| Q4 25 | 4.5% | 1.6% | ||
| Q3 25 | 2.8% | 0.8% | ||
| Q2 25 | 6.1% | 1.1% | ||
| Q1 25 | 6.3% | 2.5% | ||
| Q4 24 | 6.7% | 1.8% | ||
| Q3 24 | 7.2% | 0.3% | ||
| Q2 24 | 3.3% | 0.6% | ||
| Q1 24 | 5.1% | 0.9% |
| Q4 25 | 1.35× | -0.29× | ||
| Q3 25 | 3.03× | 0.12× | ||
| Q2 25 | 1.15× | 0.33× | ||
| Q1 25 | 1.39× | 0.46× | ||
| Q4 24 | 0.76× | 1.40× | ||
| Q3 24 | 1.48× | 0.73× | ||
| Q2 24 | 1.82× | 0.07× | ||
| Q1 24 | 1.28× | 2.20× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
PSIX
| Energy End Market | $153.4M | 80% |
| Industrial End Market | $33.3M | 17% |
| Transportation End Market | $4.6M | 2% |
